CUL9

CUL9 (PARC/H7-AP1) is a cytoplasm-localized E3 ubiquitin ligase that functions in genome maintenance, apoptotic control, and microtubule integrity (PMID:21487039, PMID:24793696). It is structurally and mechanistically distinctive: CUL9 assembles into a 1.8-MDa hexameric complex with RBX1 in which an E2-loaded RBR domain is activated by neddylation of its own cullin domain — uniquely dependent on the metazoan-specific neddylation enzyme UBE2F rather than canonical UBE2M — and positioned in trans by the adjacent CUL9-RBX1, defining a chimeric cullin-RING/RBR catalytic mechanism (PMID:38605244). Its earliest characterized biochemical feature was selective engagement of the ubiquitin-conjugating enzymes UbcH7 and UbcH8 through its RING and IBR domains, placing it within the ubiquitin/proteasome pathway (PMID:10521492). Functionally, CUL9 maintains genome integrity and governs proliferation, senescence, and apoptosis principally through direct p53 binding, since a knock-in mutation abolishing this interaction phenocopies full knockout and confers no additional DNA damage in p53-null cells (PMID:21487039, PMID:28481879). In parallel, CUL9 ubiquitylates survivin within a 3M-CUL9-survivin axis antagonized by CUL7 to preserve microtubule and mitotic fidelity (PMID:24793696), and degrades cytoplasmic cytochrome c after mitochondrial outer-membrane permeabilization to restrain caspase activation (PMID:25028716). Loss of Cul9 in mice produces spontaneous tumors, establishing a tumor-suppressor role (PMID:21487039).

1. 1999 Medium

   Established that CUL9 is an enzyme of the ubiquitin/proteasome system, answering whether its RING/IBR architecture engages specific ubiquitin-conjugating enzymes.

   Evidence Yeast two-hybrid screen and in vitro binding with domain mutants showing IBR-dependent interaction with UbcH7/UbcH8 but not UbcH5 or UbcH1

   PMID:10521492

   Open questions at the time

   • No substrate identified at this stage
   • Physiological role and cellular context undefined
   • In vitro E2 binding not linked to ubiquitylation output
2. 2011 High

   Defined CUL9 as a tumor suppressor acting through p53, answering what biological function its ligase activity serves.

   Evidence Cul9 knockout mouse showing spontaneous tumors and attenuated DNA-damage apoptosis, with a p53-binding-deficient point mutant failing to promote apoptosis

   PMID:21487039

   Open questions at the time

   • Direct ubiquitylation substrate not defined here
   • Mechanism by which p53 binding promotes apoptosis unresolved
   • Cytoplasmic-to-p53 signaling steps unmapped
3. 2014 High

   Identified survivin as a CUL9 degradation substrate and placed CUL9 in a CUL7-antagonized pathway controlling mitotic integrity.

   Evidence siRNA knockdown, ubiquitylation assays, and survivin-overexpression epistasis rescue of microtubule/mitosis defects

   PMID:24793696

   Open questions at the time

   • Molecular basis of CUL7 inhibition of CUL9 not detailed
   • Relationship between survivin and p53 axes unclear
4. 2014 Medium

   Assigned CUL9 a pro-survival role by degrading cytoplasmic cytochrome c after mitochondrial permeabilization, refining how it restrains apoptosis.

   Evidence Unbiased proteomic/biochemical identification of PARC/CUL9 as the cytochrome c ligase with proteasomal degradation assays (commentary summarizing primary study)

   PMID:25028716

   Open questions at the time

   • Reported via commentary, single lab
   • How this pro-survival role reconciles with pro-apoptotic p53 function not resolved
   • Regulation of substrate choice unknown
5. 2017 High

   Demonstrated the CUL9-p53 axis is the essential pathway for CUL9's genome-maintenance and cell-fate functions through genetic epistasis.

   Evidence Cul9Δp53 knock-in MEFs phenocopying knockout and Cul9-/-;p53-/- double-mutant analysis with cell-cycle, DNA-damage, and apoptosis readouts

   PMID:28481879

   Open questions at the time

   • Direct enzymatic events on p53 not defined
   • Mechanism linking p53 binding to S-phase/DNA-damage control unresolved
6. 2024 High

   Resolved CUL9's catalytic architecture, answering how this cullin uniquely couples cullin-RING and RBR chemistry and which neddylation enzyme activates it.

   Evidence Cryo-EM, reconstituted ubiquitylation, mutagenesis, and crosslinking mass spectrometry of the 1.8-MDa CUL9-RBX1 hexamer

   PMID:38605244

   Open questions at the time

   • Structural basis of substrate (survivin, cytochrome c, p53) recruitment not resolved
   • How UBE2F specificity is achieved mechanistically unclear
7. 2021 Low

   Raised the possibility that CUL9 abundance is itself controlled by the APC/C-FZR1 system.

   Evidence LC-MS/MS of immunoprecipitated endogenous CUL9 and FZR1 knockdown increasing CUL9 protein in pluripotent stem cells

   PMID:33705438

   Open questions at the time

   • Single Co-IP/MS without reciprocal validation
   • Direct APC/C-mediated ubiquitylation of CUL9 not demonstrated
   • CUL9 deletion did not affect APC/C subunits or cell cycle, leaving functional relevance unclear

• How CUL9's three substrate-directed activities (p53 apoptosis, survivin degradation, cytochrome c degradation) are coordinated and selected within a single chimeric ligase remains unresolved.
• No structural model of substrate engagement
• Switch between pro-apoptotic and pro-survival outputs unexplained
• Regulation of CUL9 activity in vivo incompletely mapped